Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- Drug Pricing Tomorrow: FPMAJ’s Kamoya Says Innovation Premium Meant to Head Off Future Drug Lags
August 10, 2015
- JPMA IP Committee Chair Predicts “Minimum Standard” for Data Protection Period for Drugs
August 5, 2015
- JPMA Establishes “Global Health Taskforce” in IP Committee
August 5, 2015
- “All-Japan” System Needed to Contend with Top Global Drug Makers: JPMA R&D Head
August 3, 2015
- Drug Pricing Tomorrow: JPA’s Abe Eyes Longer-Term Trial for Key Pricing Premium
July 28, 2015
- No. of Sales Reps Decreases by over 1,000 in FY2014
July 28, 2015
- Drug Pricing Tomorrow: Full Interview with Kenporen Vice President Shirakawa
July 24, 2015
- Hodanren Demands Abolishment of Innovation Premium
July 17, 2015
- US, European Lobbies Issue Joint Statement Opposing Annual Price Revisions
July 16, 2015
- Drug Pricing Tomorrow: Kenporen Veep Wants Holistic Drug Policy in FY2016 Reform
July 15, 2015
- Japan CRO Association Looking at Ways to Radically Reform Monitoring through Use of IT
July 15, 2015
- Sales by JCROA Member Companies Rise 4.9% to 143.5 Billion Yen in FY2014
July 15, 2015
- “Humanitarian Trials” Hefty Burden on Drug Makers: JPMA Regulatory Head
July 10, 2015
- JPMA Sacks Hasegawa as Vice President after Business Improvement Order
July 3, 2015
- FPMAJ Chair Hails Innovation-Fueling Policies in Govt Fiscal Plan
July 2, 2015
- JPMA Announces New Fair Competition Guidelines
July 2, 2015
- JGSM Policy Proposal Calls for Generic Volume Target of 80% by End of FY2020
July 1, 2015
- Dr Takaku Clinches Sixth Term as JAMS Chief
June 26, 2015
- Chiba Univ. Hospital to Raise Generic Drug Use Rate to 80% after July: Director-General
June 24, 2015
- FPMAJ Subcommittee Calls for Caution on “Simply Adding 2% to NHI Prices in Conjunction with Sales Tax Hike” in FY2017 Revision
June 16, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…